科学为本 · 关注健康
Science Based Health Focused
科学为本 · 关注健康
Science Based Health Focused
科学为本 · 关注健康
Science Based Health Focused
ABOUT US
XIAMEN INNODX BIOTECHNOLOGY CO., LTD.
Xiamen Innodx was founded in August , 2013 , with a registered capital of 200 million yuan . It is a member of Yangshengtang Group. It is the wholly-owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co . , Ltd . , and a high technology enterprise dedicating in chemiluminescence immunoassay IVD reagent research and development , manufacturing, and sales. In line with “ We follow the science, and concern about the health ” quality policy, the company transforms the bio-technical achievements into excellent product and service for the public.
200+
Product registration certificate
100+
Luminous research project
50+
CE certified products
98%
Self-developed and self-produced raw materials for main projects
94%
94% Coverage rate of sold products in all provinces
STAR PRODUCTS
Preoperative Diagnosis Eight Items
Including 4 generations of HIV antigen and antibody joint detection, double antibody sandwich method HCV antibody detection , double antibody sandwich method TP antibody detection , and HBV QN five items detection reagents
Advance technology and stable quality, safety-guard the whole process of medical health
Top-ranked market coverage ratio
Hepatitis Product Set
High value quantitative reagents for hepatitis B core antibody: dynamic observation of disease curative effect and effective insight into development trend
HAV, HBV, HCV, HDV, and HEV detection reagent: provide completed and special hepatitis detection solutions
HEV IgM / IgG detection reagent: recognized international gold standard
National “12th Five Year Plan” 863 “IVD”major project
Multiple national R&D patents, and Chinese patent gold award
Infection Series
Joint detection of PCT and IL - 6 , early warning and specific diagnosis advantages complemented each other , accurately diagnose bacteria infection
Whole process diagnosis and after treatment indicator appraisal for pyohemia patients
Novel Coronavirus (2019-nCoV) Antibody Detection Reagent
The first approval double antibody sandwich method Novel coronavirus ( 2019 - nCoV ) antibody detection reagent in the world
National emergent approval product
Have performance certification by multiple national authorizations
High sensitivity,specificity, and celerity of test result; many asymptomatic patients were detected under the condition that nucleic acid was negative, strengthening the epidemic controlling net
TB-IGRA:Tuberculosis Infection
Chemiluminescent Microparticle Immunoassay ———— tuberculosis infection T cell detection reagent, start a new era of TB diagnosis
Break through the limitation of traditional detection, together with new detection experience, get detection result as quick as 24 hours
The performance is same as FDA certified reagent, ranking top of its market coverage ratio in the industry
Copyright  2021  XIAMEN INNODX BIOTECHNOLOGY CO., LTD.  ALL Rights Reserved. ICP Number: 16001770-1
WeChat